CareDx, Inc (CDNA)

Market Cap	424.58M
Revenue (ttm)	280.32M
Net Income (ttm)	-190.28M
Shares Out	51.78M
EPS (ttm)	-3.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	609,497
Open	8.53
Previous Close	8.53
Day's Range	8.00 - 8.66
52-Week Range	4.80 - 12.93
Beta	1.45
Analysts	Buy
Price Target	11.00 (+34.15%)
Earnings Date	May 8, 2024

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used t...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 635
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA

Financial Performance

In 2023, CareDx's revenue was $280.32 million, a decrease of -12.89% compared to the previous year's $321.79 million. Losses were -$190.28 million, 148.4% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 34.15% from the latest price.

Price Target

$11.0

(34.15% upside)

Analyst Consensus: Buy